The present invention refers to a novel and efficient method for large-scale selective generation of y T cells, preferably human V1+y T cells, optimal for clinical application in adoptive immunotherapy of cancer. In this sense, considering that both human cord blood HPCs, currently elected as source of stem cells in the clinic, and human early thymic progenitors can efficiently generate de novo human y T cells in response to Notch signalling, and most efficiently in response to the Notch ligand Jag2, the method thus comprises inducing the differentiation of cord blood CD34+ hematopoietic progenitor cells (HPCs) and/or human CD34+ early thymic progenitors, by activating them with Jag2 Notch ligands.

The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions or methods using IL-4, a fragment or variant thereof, fused to a moiety, to increase the efficacy of an anti-cancer immunotherapy or an autoimmune therapy.

The present application discloses a novel dendritic cell preparation and a preparation method thereof. The cell preparation comprises PD-L1 negative dendritic cells and/or dendritic cells with CD40 agonists bound to the cell surface. The preparation method comprises: blocking and/or activating dendritic cells with a treatment agent, wherein the treatment agent comprises PD-L1 antibodies and/or CD40 agonists. The specific method includes adding the treatment agent to block and/or activate dendritic cells either during the dendritic cell culture stage or after completion of the culture. The dendritic cell preparation provided by the present application has enhanced maturity, improved antigen presentation, and a superior capacity to activate and amplify antigen-specific T cells compared to conventional dendritic cells, and has broad application prospects in the field of cancer immunotherapy.

Factor rich compositions produced from umbilical cord (UC) mesenchymal stem cells (MSCs) are described. Secretory UC MSCs in serum free culture conditions produce a factor rich conditioned medium which may be concentrated and filtered to obtain clinical grade products.

The present invention provides methods of expanding T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded T cells and methods of using the expanded T cells (e.g., a part of an adoptive T cell therapy).

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and/or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.

The present invention provides a method for producing recombinant growth factors using an algal expression system, which offers advantages over traditional platforms, and the algae-derived growth factors can be used to formulate cell culture media for mammalian cells without the risk of pathogen contamination or endotoxins.

Disclosed herein is a method for producing mature dendritic cells from peripheral blood mononuclear cells (PBMCs). The method includes the steps of, treating the PBMCs with a cultivating medium supplemented with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to produce immature dendritic cells; and then treating the immature dendritic cells with the cultivating medium supplemented with IL-4, GM-CSF, tumor necrosis factor alpha (TNF-), and Prostaglandin E.sub.2 (PGE.sub.2) to produce the mature dendritic cells. According to embodiments of the present disclosure, the PBMCs used in the present method are isolated from a leukocyte concentrate or a cryopreserved peripheral blood stem cells (PBSCs) stock.

A composition for culturing peripheral blood monocyte-derived regulatory T cells includes at least one antibody selected from the group consisting of anti-CD2, anti-CD3, anti-CD7, anti-CD8, anti-CD28, anti-CD30L, anti-CD40, anti-CD70, anti-CD80, anti-CD83, and anti-CD86; at least one cytokine selected from the group consisting of interleukin-2, interleukin-4, interleukin-7, interleukin-12, interleukin-15, interleukin-34, and TGF-; and superoxide dismutase. A regulatory T cell culturing method using this composition is also provided. The regulatory T cells according obtained by this method can be utilized for treatment of autoimmune diseases.